TCT-819 Prediabetes and its Impact on 1-Year Clinical Outcome After Treatment with Newer-Generation Drug-eluting Stents in 2,986 All-Comer Patients

Marlies Kok; Clemens von Birgelen; Paolo Zocca; Marije Lowik; Peter Danse; Carl Schotborgh; Martijn Scholte; Marc Hartmann; Cees Doelman; Gert Kant; R. Melvyn Tjon Joe Gin; Martin Stoel; K. Gert van Houwelingen; Gerard C.M. Linssen; Carine J.M. Doggen; Liefke van der Heijden

doi:10.1016/j.jacc.2017.09.1029

TCT-819 Prediabetes and its Impact on 1-Year Clinical Outcome After Treatment with Newer-Generation Drug-eluting Stents in 2,986 All-Comer Patients

Marlies Kok, Clemens von Birgelen, Paolo Zocca, Marije Lowik, Peter Danse, Carl Schotborgh, Martijn Scholte, Marc Hartmann, Cees Doelman, Gert Kant, R. Melvyn Tjon Joe Gin, Martin Stoel, K. Gert van Houwelingen, Gerard C.M. Linssen, Carine J.M. Doggen, Liefke van der Heijden

Health Technology & Services Research

Research output: Contribution to journal › Meeting Abstract › Academic

Abstract

BACKGROUND Prediabetes (Pre-DM) is a risk factor state for developing diabetes mellitus (DM). Yet it is unclear whether detection of Pre-DM by routine assessment of glycated haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) among patients undergoing percutaneous coronary intervention (PCI) may help identify subjects with increased event risk. We assessed in all-comers who underwent PCI with contemporary drug-eluting stents (DES) the relation between glycaemia status and 1-year clinical outcome.
METHODS HbA1c and FPG was determined in 2,362 non-DM participants in the multicenter, randomized, investigator-initiated TWENTE III trial, in order to identify Pre-DM (HbA1c 42-47mmol/mol; FPG 6.1- 6.9 mmol/L) and DM (HbA1c>=48mmol/mol; FPG >7 mmol/L). Another 624 patients had medically treated DM. The main clinical outcome parameter was a composite endpoint consisting of death, myocardial infarction, or revascularisation.
RESULTS Glycaemic state was known in 2,986 trial participants: Pre- DM was present in 324 (11%), DM in 793 (27%), and normoglycaemia in 1,869 (63%) patients. Patients with Pre-DM and DM differed from normoglycemic patients in cardiovascular risk factors. The composite clinical endpoint in Pre-DM occurred in 11.1%, in DM in 10.5%, and in normoglycemic patients in 5.7% (p

Original language	English
Pages (from-to)	B333
Journal	Journal of the American College of Cardiology
Volume	70
Issue number	18
DOIs	https://doi.org/10.1016/j.jacc.2017.09.1029
Publication status	Published - Oct 2017
Event	29th Annual Scientific Symposium of Transcatheter Cardiovascular Therapeutics, TCT 2017 - Denver, United States Duration: 29 Oct 2017 → 2 Nov 2017 Conference number: 29

Access to Document

10.1016/j.jacc.2017.09.1029

Cite this

Kok, M., von Birgelen, C., Zocca, P., Lowik, M., Danse, P., Schotborgh, C., Scholte, M., Hartmann, M., Doelman, C., Kant, G., Tjon Joe Gin, R. M., Stoel, M., Gert van Houwelingen, K., Linssen, G. C. M., Doggen, C. J. M., & van der Heijden, L. (2017). TCT-819 Prediabetes and its Impact on 1-Year Clinical Outcome After Treatment with Newer-Generation Drug-eluting Stents in 2,986 All-Comer Patients. Journal of the American College of Cardiology, 70(18), B333. https://doi.org/10.1016/j.jacc.2017.09.1029

Kok, Marlies ; von Birgelen, Clemens ; Zocca, Paolo ; Lowik, Marije ; Danse, Peter ; Schotborgh, Carl ; Scholte, Martijn ; Hartmann, Marc ; Doelman, Cees ; Kant, Gert ; Tjon Joe Gin, R. Melvyn ; Stoel, Martin ; Gert van Houwelingen, K. ; Linssen, Gerard C.M. ; Doggen, Carine J.M. ; van der Heijden, Liefke. / TCT-819 Prediabetes and its Impact on 1-Year Clinical Outcome After Treatment with Newer-Generation Drug-eluting Stents in 2,986 All-Comer Patients. In: Journal of the American College of Cardiology. 2017 ; Vol. 70, No. 18. pp. B333.

@article{c2919de56aae487abcea62d076e71e51,

title = "TCT-819 Prediabetes and its Impact on 1-Year Clinical Outcome After Treatment with Newer-Generation Drug-eluting Stents in 2,986 All-Comer Patients",

abstract = "BACKGROUND Prediabetes (Pre-DM) is a risk factor state for developing diabetes mellitus (DM). Yet it is unclear whether detection of Pre-DM by routine assessment of glycated haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) among patients undergoing percutaneous coronary intervention (PCI) may help identify subjects with increased event risk. We assessed in all-comers who underwent PCI with contemporary drug-eluting stents (DES) the relation between glycaemia status and 1-year clinical outcome.METHODS HbA1c and FPG was determined in 2,362 non-DM participants in the multicenter, randomized, investigator-initiated TWENTE III trial, in order to identify Pre-DM (HbA1c 42-47mmol/mol; FPG 6.1- 6.9 mmol/L) and DM (HbA1c>=48mmol/mol; FPG >7 mmol/L). Another 624 patients had medically treated DM. The main clinical outcome parameter was a composite endpoint consisting of death, myocardial infarction, or revascularisation.RESULTS Glycaemic state was known in 2,986 trial participants: Pre- DM was present in 324 (11%), DM in 793 (27%), and normoglycaemia in 1,869 (63%) patients. Patients with Pre-DM and DM differed from normoglycemic patients in cardiovascular risk factors. The composite clinical endpoint in Pre-DM occurred in 11.1%, in DM in 10.5%, and in normoglycemic patients in 5.7% (p",

author = "Marlies Kok and {von Birgelen}, Clemens and Paolo Zocca and Marije Lowik and Peter Danse and Carl Schotborgh and Martijn Scholte and Marc Hartmann and Cees Doelman and Gert Kant and {Tjon Joe Gin}, {R. Melvyn} and Martin Stoel and {Gert van Houwelingen}, K. and Linssen, {Gerard C.M.} and Doggen, {Carine J.M.} and {van der Heijden}, Liefke",

year = "2017",

month = oct,

doi = "10.1016/j.jacc.2017.09.1029",

language = "English",

volume = "70",

pages = "B333",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier",

number = "18",

note = "29th Annual Scientific Symposium of Transcatheter Cardiovascular Therapeutics, TCT 2017, TCT ; Conference date: 29-10-2017 Through 02-11-2017",

}

Kok, M, von Birgelen, C, Zocca, P, Lowik, M, Danse, P, Schotborgh, C, Scholte, M, Hartmann, M, Doelman, C, Kant, G, Tjon Joe Gin, RM, Stoel, M, Gert van Houwelingen, K, Linssen, GCM, Doggen, CJM & van der Heijden, L 2017, 'TCT-819 Prediabetes and its Impact on 1-Year Clinical Outcome After Treatment with Newer-Generation Drug-eluting Stents in 2,986 All-Comer Patients', Journal of the American College of Cardiology, vol. 70, no. 18, pp. B333. https://doi.org/10.1016/j.jacc.2017.09.1029

TCT-819 Prediabetes and its Impact on 1-Year Clinical Outcome After Treatment with Newer-Generation Drug-eluting Stents in 2,986 All-Comer Patients. / Kok, Marlies; von Birgelen, Clemens; Zocca, Paolo; Lowik, Marije; Danse, Peter; Schotborgh, Carl; Scholte, Martijn; Hartmann, Marc; Doelman, Cees; Kant, Gert; Tjon Joe Gin, R. Melvyn; Stoel, Martin; Gert van Houwelingen, K.; Linssen, Gerard C.M.; Doggen, Carine J.M.; van der Heijden, Liefke.

In: Journal of the American College of Cardiology, Vol. 70, No. 18, 10.2017, p. B333.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - TCT-819 Prediabetes and its Impact on 1-Year Clinical Outcome After Treatment with Newer-Generation Drug-eluting Stents in 2,986 All-Comer Patients

AU - Kok, Marlies

AU - von Birgelen, Clemens

AU - Zocca, Paolo

AU - Lowik, Marije

AU - Danse, Peter

AU - Schotborgh, Carl

AU - Scholte, Martijn

AU - Hartmann, Marc

AU - Doelman, Cees

AU - Kant, Gert

AU - Tjon Joe Gin, R. Melvyn

AU - Stoel, Martin

AU - Gert van Houwelingen, K.

AU - Linssen, Gerard C.M.

AU - Doggen, Carine J.M.

AU - van der Heijden, Liefke

N1 - Conference code: 29

PY - 2017/10

Y1 - 2017/10

N2 - BACKGROUND Prediabetes (Pre-DM) is a risk factor state for developing diabetes mellitus (DM). Yet it is unclear whether detection of Pre-DM by routine assessment of glycated haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) among patients undergoing percutaneous coronary intervention (PCI) may help identify subjects with increased event risk. We assessed in all-comers who underwent PCI with contemporary drug-eluting stents (DES) the relation between glycaemia status and 1-year clinical outcome.METHODS HbA1c and FPG was determined in 2,362 non-DM participants in the multicenter, randomized, investigator-initiated TWENTE III trial, in order to identify Pre-DM (HbA1c 42-47mmol/mol; FPG 6.1- 6.9 mmol/L) and DM (HbA1c>=48mmol/mol; FPG >7 mmol/L). Another 624 patients had medically treated DM. The main clinical outcome parameter was a composite endpoint consisting of death, myocardial infarction, or revascularisation.RESULTS Glycaemic state was known in 2,986 trial participants: Pre- DM was present in 324 (11%), DM in 793 (27%), and normoglycaemia in 1,869 (63%) patients. Patients with Pre-DM and DM differed from normoglycemic patients in cardiovascular risk factors. The composite clinical endpoint in Pre-DM occurred in 11.1%, in DM in 10.5%, and in normoglycemic patients in 5.7% (p

AB - BACKGROUND Prediabetes (Pre-DM) is a risk factor state for developing diabetes mellitus (DM). Yet it is unclear whether detection of Pre-DM by routine assessment of glycated haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) among patients undergoing percutaneous coronary intervention (PCI) may help identify subjects with increased event risk. We assessed in all-comers who underwent PCI with contemporary drug-eluting stents (DES) the relation between glycaemia status and 1-year clinical outcome.METHODS HbA1c and FPG was determined in 2,362 non-DM participants in the multicenter, randomized, investigator-initiated TWENTE III trial, in order to identify Pre-DM (HbA1c 42-47mmol/mol; FPG 6.1- 6.9 mmol/L) and DM (HbA1c>=48mmol/mol; FPG >7 mmol/L). Another 624 patients had medically treated DM. The main clinical outcome parameter was a composite endpoint consisting of death, myocardial infarction, or revascularisation.RESULTS Glycaemic state was known in 2,986 trial participants: Pre- DM was present in 324 (11%), DM in 793 (27%), and normoglycaemia in 1,869 (63%) patients. Patients with Pre-DM and DM differed from normoglycemic patients in cardiovascular risk factors. The composite clinical endpoint in Pre-DM occurred in 11.1%, in DM in 10.5%, and in normoglycemic patients in 5.7% (p

UR - http://www.mendeley.com/research/tct819-prediabetes-impact-1year-clinical-outcome-after-treatment-newergeneration-drugeluting-stents

U2 - 10.1016/j.jacc.2017.09.1029

DO - 10.1016/j.jacc.2017.09.1029

M3 - Meeting Abstract

VL - 70

SP - B333

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 18

T2 - 29th Annual Scientific Symposium of Transcatheter Cardiovascular Therapeutics, TCT 2017

Y2 - 29 October 2017 through 2 November 2017

ER -

TCT-819 Prediabetes and its Impact on 1-Year Clinical Outcome After Treatment with Newer-Generation Drug-eluting Stents in 2,986 All-Comer Patients

Abstract

Access to Document

Other files and links

Fingerprint

Cite this